Bayer said on Tuesday it was preparing market launches this year of two new drugs that could each have annual peak sales of ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program ...

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Promulgating three core myths, advocates for maintaining the status quo of public funding have been active in the media, but ...

Pfizer delayed the announcement of its COVID-19 vaccine until after the 2020 election when it thought Donald Trump was defeated.

The talks between the administration and the industry, which have been taking place behind closed doors, have given some ...

Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...